Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974602 | 0.86 | METAP2 (0.49) | PIM1JAK2CDK9CDK5CAMK2A | |
| SCHEMBL30972537 | 0.83 | PIM3 (0.59) | PIM1JAK2CDK9CDK5CAMK2A | |
| SCHEMBL182445 | 0.82 | JAK2 (0.60) | PIM1JAK2CDK9CDK5CAMK2A | |
| SCHEMBL13377623 | 0.78 | AR (0.55) | PIM1JAK2CDK9CDK5CAMK2A | |
| SCHEMBL38651948 | 0.76 | HSD17B10 (0.56) | PIM1JAK2CDK9CDK5CAMK2A | |
| SCHEMBL1298075 | 0.75 | PIM3 (0.71) | PIM1JAK2CDK9CDK5CAMK2A | |
| SCHEMBL30972538 | 0.75 | PIM3 (0.71) | PIM1JAK2CDK9CDK5CAMK2A | |
| SCHEMBL8814308 | 0.74 | KDM4E (0.64) | CDK5CAMK2ACHEK1PRKD3PRKACA | |
| SCHEMBL22457095 | 0.73 | CCNE2 (0.64) | PIM1JAK2CDK9CDK5CAMK2A | |
| SCHEMBL5879297 | 0.72 | CHEK1 (0.59) | PIM1JAK2CDK9CDK5CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135809-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| US-20170305906-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-20170305906-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-20170305906-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-9701676-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701676-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-11 | — | — | US | disclosed |
| EP-2887803-A1 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2015-07-01 | — | — | EP | disclosed |
| US-8664233-B2 | Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664233-B2 | Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664233-B2 | Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20140057900-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057900-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031986-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031986-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2104675-B1 | SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | MEDICINES CO LEIPZIG GMBH (DE) | 2012-10-31 | — | — | EP | disclosed |
| EP-2104675-B1 | SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | MEDICINES CO LEIPZIG GMBH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2008077631-A1 | SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057900-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | PIM1 4633/4885JAK2 4035/4885CDK9 341/4885 |
| US-20110021511-A1 | SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | BCL6, BCL3, BCL6B | PIM1 265/4885JAK2 64/4885CDK9 1290/4885 |
| US-20190135809-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | PIM1 4633/4885JAK2 4035/4885CDK9 341/4885 |
| US-20170305906-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | PIM1 4633/4885JAK2 4035/4885CDK9 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.